Meta AnalysisID 2465
N-乙酰半胱氨酸作为儿童孤独症谱系障碍辅助治疗的疗效：一项Meta分析
CRD42020209272
Is Oral N- Acetylcysteine efficacious as an adjuvant treatment in improving Abberant Behavior Checklist scores in children with Autism Spectrum Disorder?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2465
- Evidence Id
- 11023
- Core Evidence Id
- 11023
- Source Meta Analysis Id
- 2414
- Herb2 Meta Analysis Id
- HBMA002414
- Crd Id
- CRD42020209272
- Title
- Efficacy of N- Acetylcysteine as an adjuvant treatment for children with Autism Spectrum Disorder: A Meta- Analysis
- Review Question
- Is Oral N- Acetylcysteine efficacious as an adjuvant treatment in improving Abberant Behavior Checklist scores in children with Autism Spectrum Disorder?
- Study Type Included
- Randomized control study (RCT) will be used for this review
- Condition Being Studied
- Autism Spectrum Disorder (ASD) is a pervasive neurodevelopmental condition that can be characterized by three core defecits: (1) communication difficulties, (2) impairments in social interaction and (3) repetitive, restricted behaviors. It is estimated that approximately 1-2% of the population is affected by this condition
- Participant
- Inclusion Criteria a. Randomized Controlled Trial b. Published between January 2012- April 2020 c. Published in the English language d. Patients aged 0- 18 years old e. Diagnosis of autism spectrum disorder based on DSM- IV- TR/ V criteria, Autism Diagnostic Observation Schedule (ADOS) and/or Autism Diagnostic Interview- Revised (ADI-R) f. Use of N- Acetylcysteine as an adjuvant treatment for ASD g. Use of concomitant medications are permitted with dosage not markedly changed at least 2 weeks from the start of the study h. No plans of changing psychosocial interventions throughout the course of the study i. Outcome of interest with data on Aberrant Behavior Checklist (ABC) subscale scores 2. Exclusion Criteria a. Retrospective studies, case control studies, experimental (in vivo) studies b. Studies not in the English language c. Studies not involving pediatric patients d. Patients with active medical problems, such as unstable seizures, profound cognitive impairment, significant physical illness, kidney disease, liver disease, or unstable asthma e. Patients with intake of medications with glutaminergic effects (i.e. amantadine, dextromethorphan, memantine, D-cycloserine, lamotrigine, riluzole) f. Studies with no relationship to ASD g. Studies with no relationship to N acetylcysteine h. Studies with no outcome of interest
- Animal
- Human Disease Modelled
- Intervention
- Oral N- Acetylcysteine is widely available prodrug of cysteine, the rate limiting agent in glutathione synthesis. Its potential use in the treatment of neuropsychiatric behaviors is brought about by two mechanisms: (1) anti- oxidative property and (2) extracellular glutamate regulation.
- Comparator Control
- Placebo
- Main Outcome
- Improvement of scores across the Aberrant Behavior Checklist: (1) irritability, (2) stereotypic behaviors, (3) hyperactivity and non- compliance, (4) inappropriate speech and (5) lethargy and social withdrawal. Measures of effect The variables identified from eligible journals will be recorded in numerical form and subjected to appropriate statistical treatment. Mean difference (MD) and standard deviation (SD) will be used to determine difference between outcomes. The analytic approach and software provided by Cochrane Collaboration (RevMan Version 5.4) will be used for all analyses and will be interpreted using forest plot.
- Outcome Measure
- Additional Outcome
- Determination of adverse effects of N- acetylcysteine in pediatric patients with ASD Measures of effect Variables will be recorded in numerical form. Analytical approach provided by Cochrane Collaboration will be used for all analysis and will be interpreted using forest plot.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Acetylcysteine; Autism Spectrum Disorder; Case-Control Studies; Child; Humans
- Contact
- Leoniza Marie Monzon [email protected]
- Organisational Affiliation
- De La Salle University Medical Center
- Funding Source
- No sponsors for this review
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Philippines
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-09-14
- Registration Date
- 2020-10-15
- Anticipated Start Date
- 2020-09-14
- Anticipated Completion Date
- 2020-10-15
- Title Cn
- N-乙酰半胱氨酸作为儿童孤独症谱系障碍辅助治疗的疗效：一项Meta分析
- Title En
- Efficacy of N- Acetylcysteine as an adjuvant treatment for children with Autism Spectrum Disorder: A Meta- Analysis
- Bilingual Status
- complete